Journal Information
Vol. 86. Issue 6.
Pages 825-826 (November - December 2020)
Vol. 86. Issue 6.
Pages 825-826 (November - December 2020)
Letter to the Editor
Open Access
Laryngo-tracheobronchial amyloidosis
Amiloidose laringotraqueobronquica
Visits
3695
Juan Pablo Uyaguaria, Pedro Jose Quizhpeb, Evelise Limaa,
Corresponding author
eveliselima53@gmail.com

Corresponding author.
a Universidade de São Paulo, Hospital de Clínicas, Instituto do Coração, Serviço de Endoscopia Respiratória, São Paulo, SP, Brazil
b Universidade de São Paulo, Hospital de Clínicas, Instituto do Coração, Serviço de Pneumologia, São Paulo, SP, Brazil
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text
Dear Editor,

We read the article by Caporrino Neto J et al., which calls attention to the clinical diversity of laryngeal amyloidosis, a localized variant of amyloidosis, representing up to 1% of benign laryngeal tumors.1 We would like to highlight the importance of assessing the entire airway in cases of aerodigestive amyloidosis.

We reported a case of a 52-year-old man with dysphonia for 7 months. He denied dyspnea and had no comorbidities. The physical examination, pulmonary function test and computed tomography (CT) of the neck and chest showed no alterations.

During direct laryngoscopy, yellowish infiltrative lesions were observed in the nasopharynx and epiglottis (Fig. 1 A and B), suggestive of amyloidosis. Due to the observed alterations, we chose to perform a tracheobronchial tree evaluation, and similar lesions were identified in the entire length of the trachea (Fig. 1C) and in the bronchial subsegments (Fig. 1D). Biopsies of the epiglottis and right main bronchus lesions confirmed the diagnosis of laryngo-tracheobronchial amyloidosis (LTBA).

Fig. 1.

Tracheal lesions.

(0.15MB).

Primary LTBA is a rare disease, characterized by submucosal plaques or nodules of amyloid deposits in the airways, which can be localized or multifocal. It represents only 0.5 % of all symptomatic tracheobronchial lesions and is rarely associated with systemic amyloidosis.2–4

Symptoms are nonspecific, such as coughing, dyspnea, wheezing, hemoptysis and dysphonia, which can delay diagnosis or be mistaken by other respiratory illnesses. Pulmonary function testing and neck and chest computed tomography results may be normal.4,5

Endoscopic visualization is the main diagnostic tool and the biopsy is the gold standard for the diagnosis.5 The presence of homogeneous extracellular amyloid deposits, eosinophilic amorphous material and green birefringence under polarization microscopy with Congo Red staining confirm the diagnosis.5

Although it is not closely associated with systemic amyloidosis, the latter should be ruled out through serum and urine electrophoresis tests to detect monoclonal proteins, together with an echocardiography to investigate cardiomyopathy secondary to amyloid deposits.4,5

There is no specific treatment. Mechanical excision, balloon dilation, stenting, argon plasma coagulation, laser, cryotherap, electrocautery and tracheostomy are alternatives that have been described for the treatment of symptomatic patients.3–5

In conclusion, LTBA is a rare disease that should be considered in patients with subacute symptoms of airway obstruction without an adequate response to treatment and should be investigated in patients with aerodigestive amyloidosis. The diagnostic method of choice is respiratory endoscopy with the identification of yellowish infiltrative lesions, since the definitive diagnosis is attained through the biopsy of lesions.

Conflicts of interest

The authors declare no conflicts of interest.

References
[1]
J.N. Caporrino, N.S.C. Alves, L.A. Gondra.
Laryngeal amyloidosis presenting as false vocal fold bulging: clinical and therapeutic aspects.
Braz J Otorhinolaryngol, 81 (2015), pp. 219-221
[2]
R.C. Newton, S.V. Kemp, G.Z. Yang, A. Darzi, M.N. Sheppard, P.L. Shah.
Tracheobronchial amyloidosis and confocal endomicroscopy.
Respiration, 82 (2011), pp. 209-211
[3]
A. Lal, J. Akhtar, M.S. Khan, Y. Chen, Y. Goldman.
Primary endobronchial amyloidosis: A rare case of endobronchial tumor.
Respir Med Case Rep, 23 (2018), pp. 163-166
[4]
H.W. Kang, H.J. Oh, H.Y. Park, C.K. Park, H.J. Shin, J.H. Lim, et al.
Endobronchial amyloidosis mimicking bronchial asthma: a case report and review of the literature.
Open Med (Wars), 11 (2016), pp. 174-177
[5]
X. Lu, B. He, G. Wang, B. He, L. Wang, Q. Chen.
Bronchoscopic diagnosis and treatment of primary tracheobronchial amyloidosis: a retrospective analysis from China.
Biomed Res Int, 2017 (2017),

Please cite this article as: Uyaguari JP, Quizhpe PJ, Lima E. Laryngo-tracheobronchial amyloidosis. Braz J Otorhinolaryngol. 2020;86:825–6.

Study carried out at the Respiratory Endoscopy Service of Instituto do Coração do Hospital de Clínicas da Faculdade de Medicina of Universidade de São Paulo.

Copyright © 2020. Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial
Idiomas
Brazilian Journal of Otorhinolaryngology (English Edition)
Article options
Tools
en pt
Announcement Nota importante
Articles submitted as of May 1, 2022, which are accepted for publication will be subject to a fee (Article Publishing Charge, APC) payment by the author or research funder to cover the costs associated with publication. By submitting the manuscript to this journal, the authors agree to these terms. All manuscripts must be submitted in English.. Os artigos submetidos a partir de 1º de maio de 2022, que forem aceitos para publicação estarão sujeitos a uma taxa (Article Publishing Charge, APC) a ser paga pelo autor para cobrir os custos associados à publicação. Ao submeterem o manuscrito a esta revista, os autores concordam com esses termos. Todos os manuscritos devem ser submetidos em inglês.